Acta Pharmaceutica Sinica B (Nov 2021)

Bruceine D inhibits HIF-1α-mediated glucose metabolism in hepatocellular carcinoma by blocking ICAT/β-catenin interaction

  • Rui Huang,
  • Lijun Zhang,
  • Jinmei Jin,
  • Yudong Zhou,
  • Hongwei Zhang,
  • Chao Lv,
  • Dong Lu,
  • Ye Wu,
  • Hong Zhang,
  • Sanhong Liu,
  • Hongzhuan Chen,
  • Xin Luan,
  • Weidong Zhang

Journal volume & issue
Vol. 11, no. 11
pp. 3481 – 3492

Abstract

Read online

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths, characterized by highly hypoxic tumor microenvironment. Hypoxia-inducible factor-1α (HIF-1α) is a major regulator involved in cellular response to changes of oxygen levels, supporting the adaptation of tumor cells to hypoxia. Bruceine D (BD) is an isolated natural quassinoid with multiple anti-cancer effects. Here, we identified BD could significantly inhibit the HIF-1α expression and its subsequently mediated HCC cell metabolism. Using biophysical proteomics approaches, we identified inhibitor of β-catenin and T-cell factor (ICAT) as the functional target of BD. By targeting ICAT, BD disrupted the interaction of β-catenin and ICAT, and promoted β-catenin degradation, which in turn induced the decrease of HIF-1α expression. Furthermore, BD could inhibit HCC cells proliferation and tumor growth in vivo, and knockdown of ICAT substantially increased resistance to BD treatment in vitro. Our data highlight the potential of BD as a modulator of β-catenin/HIF-1α axis mediated HCC metabolism.

Keywords